Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Top Cited Papers
- 1 February 2005
- journal article
- research article
- Published by Elsevier BV in Cancer Cell
- Vol. 7 (2), 129-141
- https://doi.org/10.1016/j.ccr.2005.01.007
Abstract
No abstract availableThis publication has 55 references indexed in Scilit:
- Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CMLBlood, 2004
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinibBlood, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatmentBlood, 2002
- A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemiasBlood, 2002
- Roots of Clinical Resistance to STI-571 Cancer TherapyScience, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000